Schizophrenia trials in China: a survey by Chakrabarti, A et al.
Schizophrenia trials in China: a survey
A Chakrabarti1, CE Adams2, J Rathbone2, J Wright2, J Xia2, W Wong2, P Von
Reibnitz3, C Koenig3, S Baier,3 C Pfeiffer3, J Blatter3, M Mantz3, K Kloeckner3
1. Specialist Registrar in General Adult Psychiatry, Newsam Centre, Seacroft
Hospital, York Road, Leeds, West Yorkshire, LS14 6UH.
2. University of Leeds, Leeds, UK.
3. University of Ulm, Schule für Medizinische Dokumentation, Ulm, Germany.
Corresponding author: Abhijit Chakrabarti, Specialist Registrar in General Adult
Psychiatry, Newsam Centre, Seacroft Hospital, York Road, Leeds, West Yorkshire,
LS14 6UH.
Email address: abhijitchakrabarti@yahoo.co.uk
Telephone number: +44 (0) 113 343 3409
Fax number: +44 (0) 113 343 2723
Abstract
Introduction: China’s biomedical research activity is increasing and this literature is
becoming more accessible online. Our aim was to survey all randomised control
schizophrenia trials (RCTs) in one Chinese bibliographic database.
Methods: Chinese Academic Journals was electronically searched for RCTs and all
relevant citations were also sought on PubMed to ascertain global accessibility.
Results: The search identified 3275 records, of which 982 were RCTs relevant to
schizophrenia. 71% (699) could be found by using English phrases. All the main body of
text of the 982 papers was in Mandarin. On average, these trials involved about 100
people, with interventions and outcome measures familiar to schizophrenia trialists
world-wide. Four of the 982 records (<1%) were identified on PubMed.
Conclusion: Those undertaking systematic reviews should search the Chinese
literature for relevant material. Failing to do this will leave the results of systematic
reviews prone to random error, or bias or both.
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Significant outcomes:
An ever-increasing number of schizophrenia trials are originating from China.
The majority of these trials were researching recognizable drug and psychological
treatments and using familiar outcome measures.
Less than 1% of these trials were identified on PubMed.
Limitations:
Multiple publication was difficult to recognize.
Manual searching of the Chinese journals was not preformed.
Introduction
The People’s Republic of China is the most populous country in the world. With over 1.3
billion people (five times the population of the USA, three times that of the EU) (1) and
with a life time prevalence of 1%, an estimated 1.3 million people in China suffer from
schizophrenia. In China, recently, the total number of hospitals and clinics has expanded
to over 300,000 and the number of practising doctors to 1.8 million. Developments such
as almost doubling the life expectancy and dramatically lowering the infant mortality rate
over the last 30 years, emphasizes the improvement in the country’s health care (2).
Also, over the last two decades China’s economy has strengthened with the Gross
Domestic Product (GDP) quadrupling since 1978 (2003 estimate).
It is known that the GDP is one key predictor of national output of schizophrenia trials (3).
It seems likely that this expansion in health care and in the economy in China has been
paralleled by research effort and output but, for those using English, the Chinese
literature has not been easy to access. In the last few years, however, things have
changed and more of the Chinese biomedical literature has become accessible. For
example, CAJ (Chinese Academic Journals), a bibliographic database indexing the
contents of 140 Chinese biomedical journals is now online (4) and can be searched
through an English or Chinese interface with full text reports to download.
Previous studies have suggested that literature from less well known sources is not
accessible to those searching only mainstream databases (5,6,7,8). For researchers
undertaking systematic reviews of the effects of care for people with schizophrenia,
failing to include relevant studies can lead to less precise results than would otherwise
be possible, and, at worst, biased findings (9).
Aim of the study
To identify and survey all randomized trials in the CAJ relevant to the care of people with
schizophrenia.
Material and Methods
The Eastview Online CAJ was accessed initially on their one month free trial offer and
though the University of Leeds’ subscription thereafter. We searched CAJ in July 2005
(1994-present) in English using the phrase: ((antipsychotic OR antipsychotics OR
extrapyram, OR psychosis OR psychotic OR schizophrenic OR tardive dyskinesia OR
chronic schizophrenia) AND (randomi, OR double-blind, )) in the title or abstract. JX, a
Chinese native speaker, translated English terms into traditional Chinese characters and
repeated the search using the phrase: ((精神分裂症 OR抗精神病的 OR椎体外系 OR精
神病 OR患精神病的 OR动作障碍 OR慢性精神分裂症) AND (随机化 OR随机选择 OR
双盲 OR随机)) in title or abstract (see Table 1).
Table 1: Chinese translation of the English search terms
精神分裂症 Schizophrenia
抗精神病的 Antipsychotic
椎体外系 Extrapyramidal
精神病 Psychosis
患精神病的 Psychotic
慢性精神分裂症 Chronic schizophrenia
随机化 or随机选择 Randomization
双盲 Double blind
随机 Randomly
动作障碍 Tardive dyskinesia
Searching the CAJ database involved using the ‘advanced search’ screen to build
search strings with the familiar Boolean operators, and/or/not (i.e. to combine the search
terms). This screen, allows use of the ‘search in keywords’ to collectively scan title,
keyword and abstract fields and displays all details of results.
We then downloaded records, managed them within a MS Access database and
removed duplicates. Records were manually scanned for randomized control trials or
controlled clinical trials (studies likely to have been randomized but in which description
of allocation is unclear) relevant to the care of people with schizophrenia by CK, PR and
AC, who all worked independently. This selection was reliable (kappa 0.98). Then CK,
PR and AC working together, extracted data on the content and quality of the
schizophrenia trials. WW and JX, Chinese native speakers, repeated this for studies only
in Mandarin. Finally, MEDLINE (PubMed) database was examined, in order to ascertain
how many records of these schizophrenia trials from CAJ were disseminated in PubMed.
Results
The search identified 3275 records. After checking for duplicates and relevance we
found a total of 982 records that reported randomized studies relevant to schizophrenia.
Of these, 29% (283) were identified by solely the Mandarin phrases but 71% (699) could
be found by using English phrases (Figure 1). Twenty seven percent of records were
solely in Mandarin. An English record predicted an English abstract in the full text of the
paper, but all the main body of text of the 982 papers was in Mandarin. Using data from
the Cochrane Schizophrenia Group’s comprehensive register of trials (10) we calculated
the proportions of all schizophrenia trials that originate from China in recent years
(Figure 2.).
The average number of people in these Chinese schizophrenia trials was about 100
(mean 98.6, SD 96.2, range 11-1471, median 78, mode 60). The most common drug
interventions under evaluation were clozapine (28%), risperidone (24%), chlorpromazine
(14%), quetiapine (7%) and haloperidol (5%), but, over the last 4 years, 45% of
schizophrenia trials in CAJ involved psychological interventions. The most common
outcome scales used in all these trials were familiar to researchers world-wide (BPRS -
38%, TESS - 36%, PANSS - 25%, SANS - 20%, SAPS - 8%, SDSS - 6%).
PubMed, the service of the US National Library of Medicine, includes over 16 million
citations from MEDLINE and other life science journals. MEDLINE, the largest
component of PubMed, covers over 4,800 journals from more than 70 different countries
(11). We found only four out of 982 reports (<1%) of these Chinese schizophrenia trials
in PubMed.
Discussion
CAJ is only one of an increasing number of substantial Chinese biomedical literature
databases (12) and, even within it, our search was limited. It is feasible that the
improved China National Knowledge Infrastructure (CNKI) format for CAJ would be yet
more productive. We also could have experienced some double counting because of not
recognizing multiple publication. We have not manually searched any Chinese medical
journals listed in CAJ to ascertain what proportion of trials our electronic search
identified. It is also possible we have not identified some schizophrenia trials from China
published in Western journals.
Nevertheless, this study suggests that an ever-increasing number of randomized trials
relevant to people with schizophrenia originate from China. About one quarter of the
world’s population of people with schizophrenia is Chinese. This study suggests that, in
the last few years, at least the same proportion of all reports of randomized trials
relevant to this group can be readily identified in the Chinese literature.
Our survey could not go beyond identifying studies that seemed to be randomized trials.
We know of work suggesting how Chinese studies may use methodological descriptions
such as ‘randomized’ liberally (13,14).
Even if this is so, and a higher than average proportion of what we have identified is not
of good quality, it is currently difficult to ascertain which of the hundreds of studies are
indeed of value. We argue, all should be considered by those undertaking systemic
reviews. In addition, if this scientific activity in China reflects that seen in the plastics and
electronic industry, a period of variable quality will be followed by systematic
improvements and then dominance of the field (15).
These Chinese trials are, on average, larger than their counterparts from other countries
(16). Several investigate interventions not commonly evaluated elsewhere, such as
traditional Chinese medicines (17) and Morita therapy (18) and highlight effects of
potentially valuable treatments not known to the rest of the world. However, by far the
majority of the studies we identified were evaluating recognizable drug and
psychological treatments and measuring outcomes in familiar ways.
Systematic reviews are now important influences on practice, being an integral part of
guidelines (19). If the results of randomized trials originating from the People’s Republic
of China do not fundamentally differ from trials from other parts of the world, omitting
them from systematic reviews may result in losing opportunities to identify real evidence
of benefit or harm (Type II errors) (9). If, however, the results of trials from China are
different from those more familiar to the rest of the world, reviews using only more
accessible studies could be biased and misleading (Type I errors) (9). At present all we
can be sure of is that this large body of evidence is relevant and should be considered.
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Figure 1: Number of schizophrenia trials in CAJ per year
Figure 2: Number of reports of schizophrenia trials worldwide
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